Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

8.09
Delayed Data
As of Jul 13
 +0.04 / +0.50%
Today’s Change
5.02
Today|||52-Week Range
13.30
-3.80%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$350.7M

Company Description

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Contact Information

Bellicum Pharmaceuticals, Inc.
Life Science Plaza
Houston Texas 77030
P:(832) 384-1100
Investor Relations:

Employees

Shareholders

Individual stakeholders23.68%
Mutual fund holders23.65%
Other institutional19.74%

Top Executives

Richard A. FairPresident, Chief Executive Officer & Director
Alan A. MussoChief Financial Officer & Treasurer
David M. SpencerChief Technology Officer
William GrossmanChief Medical Officer
Joseph Howard SenesacVice President-Viral Vector Development